Cost-effectiveness analysis of budesonide/formoterol SMART therapy versus salmeterol/fluticasone plus as-needed SABA among patients ≥12 years with moderate asthma from the Chinese societal perspective

Keruo Zhou, Min Zhang, Chenyu Zuo, Xiazhen Xie, Jianwei Xuan

Open source

DOI
10.1080/13696998.2024.2385191
Published
2024-08-17
Container
Journal of Medical Economics
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/13696998.2024.2385191,
  title = {Cost-effectiveness analysis of budesonide/formoterol SMART therapy versus salmeterol/fluticasone plus as-needed SABA among patients ≥12 years with moderate asthma from the Chinese societal perspective},
  author = {Keruo Zhou and Min Zhang and Chenyu Zuo and Xiazhen Xie and Jianwei Xuan},
  year = {2024},
  journal = {Journal of Medical Economics},
  doi = {10.1080/13696998.2024.2385191},
  url = {https://doi.org/10.1080/13696998.2024.2385191}
}

RIS

TY  - JOUR
TI  - Cost-effectiveness analysis of budesonide/formoterol SMART therapy versus salmeterol/fluticasone plus as-needed SABA among patients ≥12 years with moderate asthma from the Chinese societal perspective
AU  - Keruo Zhou
AU  - Min Zhang
AU  - Chenyu Zuo
AU  - Xiazhen Xie
AU  - Jianwei Xuan
PY  - 2024
JO  - Journal of Medical Economics
DO  - 10.1080/13696998.2024.2385191
UR  - https://doi.org/10.1080/13696998.2024.2385191
ER  - 

APA

Zhou, K., Zhang, M., Zuo, C., Xie, X., & Xuan, J. (2024). Cost-effectiveness analysis of budesonide/formoterol SMART therapy versus salmeterol/fluticasone plus as-needed SABA among patients ≥12 years with moderate asthma from the Chinese societal perspective. Journal of Medical Economics. https://doi.org/10.1080/13696998.2024.2385191

Source records